Surrogate Markers of Small Fiber Damage in Human Diabetic Neuropathy

  1. Cristian Quattrini1,
  2. Mitra Tavakoli1,
  3. Maria Jeziorska2,
  4. Panagiotis Kallinikos1,
  5. Solomon Tesfaye3,
  6. Joanne Finnigan4,
  7. Andrew Marshall4,
  8. Andrew J.M. Boulton1,
  9. Nathan Efron5 and
  10. Rayaz A. Malik1
  1. 1Division of Cardiovascular Medicine, University of Manchester, Manchester Diabetes Centre and Manchester Royal Infirmary, Manchester, U.K
  2. 2Division of Regenerative Medicine, University of Manchester, Manchester, U.K
  3. 3Diabetes Research Unit, Royal Hallamshire Hospital, Sheffield, U.K
  4. 4Department of Neurophysiology, Manchester Royal Infirmary, Manchester, U.K
  5. 5Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
  1. Address correspondence and reprint requests to Dr. R.A. Malik, Division of Cardiovascular Medicine, University of Manchester, Manchester, M13 9NT, U.K. E-mail: rayaz.a.malik{at}man.ac.uk

Abstract

Surrogate markers of diabetic neuropathy are being actively sought to facilitate the diagnosis, measure the progression, and assess the benefits of therapeutic intervention in patients with diabetic neuropathy. We have quantified small nerve fiber pathological changes using the technique of intraepidermal nerve fiber (IENF) assessment and the novel in vivo technique of corneal confocal microscopy (CCM). Fifty-four diabetic patients stratified for neuropathy, using neurological evaluation, neurophysiology, and quantitative sensory testing, and 15 control subjects were studied. They underwent a punch skin biopsy to quantify IENFs and CCM to quantify corneal nerve fibers. IENF density (IENFD), branch density, and branch length showed a progressive reduction with increasing severity of neuropathy, which was significant in patients with mild, moderate, and severe neuropathy. CCM also showed a progressive reduction in corneal nerve fiber density (CNFD) and branch density, but the latter was significantly reduced even in diabetic patients without neuropathy. Both IENFD and CNFD correlated significantly with cold detection and heat as pain thresholds. Intraepidermal and corneal nerve fiber lengths were reduced in patients with painful compared with painless diabetic neuropathy. Both IENF and CCM assessment accurately quantify small nerve fiber damage in diabetic patients. However, CCM quantifies small fiber damage rapidly and noninvasively and detects earlier stages of nerve damage compared with IENF pathology. This may make it an ideal technique to accurately diagnose and assess progression of human diabetic neuropathy.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 18 May 2007. DOI: 10.2337/db07-0285.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted May 12, 2007.
    • Received February 28, 2007.
« Previous | Next Article »Table of Contents